Why does TRT cause hair loss? The DHT mechanism explained
When testosterone enters circulation, a portion of it is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT is a more potent androgen than testosterone itself, and it binds with high affinity to androgen receptors in hair follicles.
In genetically susceptible individuals, this binding triggers a process called follicle miniaturization: the growth phase of the hair cycle shortens over successive cycles, producing progressively finer, shorter hairs until the follicle becomes dormant. This is androgenetic alopecia, or male-pattern baldness.
TRT raises testosterone levels, which means more substrate is available for DHT conversion. In a man with high genetic sensitivity, this can accelerate the thinning process that was already underway or that was going to occur eventually. In a man with low genetic sensitivity, the elevated testosterone may produce little to no change in hair density because his follicles do not respond strongly to DHT signals.
Who is actually at risk of hair loss on TRT?
The strongest predictors of TRT-related hair loss are:
- Family history: Androgenetic alopecia is polygenic, but a strong family pattern on either side (maternal or paternal) increases susceptibility. The gene for the androgen receptor is X-linked, which partly explains why the maternal grandfather has historically been cited as a predictor, though the picture is more complex than that single gene.
- Existing thinning: Men already experiencing hairline recession or crown thinning before starting TRT have established follicle sensitivity. TRT is more likely to accelerate an existing trajectory than to create one from scratch.
- Delivery route: Topical testosterone formulations (gels, creams) applied to skin convert disproportionately to DHT because skin tissue is rich in 5-alpha reductase. Injected forms typically produce lower DHT-to-testosterone ratios. This is a meaningful variable in protocol design.
- 5-alpha reductase activity: Some men convert testosterone to DHT more efficiently than others. Serum DHT labs, drawn as part of standard TRT monitoring, give a clinician visibility into how much conversion is occurring.
TRT only accelerates hair loss in men whose follicles are genetically sensitive to DHT — for everyone else, raising testosterone changes little about hair density.
Telogen effluvium or androgenetic loss — which kind of shedding is it?
Not all shedding that starts after beginning TRT is androgenetic. A distinct pattern called telogen effluvium can occur when any significant physiological change, including a hormonal shift, causes a larger-than-normal percentage of follicles to enter the resting (telogen) phase simultaneously, resulting in a diffuse shed that typically peaks around 3 months after the trigger.
Telogen effluvium-related shedding is usually temporary. As hormone levels stabilize, the follicle cycling normalizes and the shed typically resolves. The distinguishing feature is that telogen effluvium produces diffuse loss across the scalp rather than the patterned recession or crown thinning of androgenetic alopecia.
Clinicians monitoring a patient through TRT initiation watch for both patterns because they require different management responses.
How can you mitigate hair loss on TRT?
For men who want to optimize testosterone levels without accelerating hair loss, a clinician-supervised approach offers several evidence-informed options:
- Route optimization: Switching from topical formulations to injected testosterone can lower the DHT-to-testosterone ratio meaningfully in some patients.
- Finasteride: An FDA-approved oral 5-alpha reductase inhibitor that blocks the conversion of testosterone to DHT. It is used for both benign prostatic hyperplasia (BPH) and androgenetic alopecia. Co-prescribing finasteride with TRT is an established strategy discussed in clinical practice for hair-conscious patients.
- Dutasteride: A dual 5-alpha reductase inhibitor (blocking both Type I and Type II isoforms) that is more potent than finasteride at suppressing DHT. Used off-label for hair loss in some clinical contexts.
- Topical minoxidil: FDA-approved for male-pattern hair loss. Can be used concurrently with TRT and with 5-alpha reductase inhibitors; works through a different mechanism (extending the anagen growth phase) rather than blocking DHT.
- DHT monitoring: Routine serum DHT labs allow a clinician to see how much conversion is occurring and adjust the protocol accordingly rather than guessing.
These are clinical decisions that require a prescribing clinician to weigh your medical history, current medications, and goals. They are not suitable as self-directed supplementation.
What does monitoring look like?
Standard TRT monitoring panels typically include total testosterone, free testosterone, estradiol, hematocrit, PSA (in men over 40), and increasingly DHT. A clinician who orders baseline and follow-up DHT alongside the rest of the panel can catch disproportionate conversion early and adjust before accelerated shedding becomes established.
This is one of the core practical advantages of clinician-supervised therapy compared to unsupervised use: the feedback loop exists, and protocol adjustments can be made in response to real lab data rather than symptoms alone.
At PepScribe, testosterone therapy is evaluated through a clinician intake that includes health history, goals, and relevant labs before any protocol is prescribed. No shortcuts on the clinical review process. All medications are compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.
If you are considering testosterone therapy and have concerns about hair loss, the right move is to surface that concern explicitly during your intake so the clinician can factor it into protocol design from the start.
Frequently asked questions
Does TRT cause hair loss?
TRT can accelerate male-pattern hair loss in men who are genetically predisposed to androgenetic alopecia. Testosterone converts to DHT via the 5-alpha reductase enzyme, and DHT miniaturizes follicles sensitive to androgen signaling. Men with no genetic susceptibility are unlikely to experience significant shedding from TRT alone.
How quickly does TRT-related hair loss start?
There is no fixed timeline. Some men with high genetic susceptibility notice increased shedding within the first few months of starting TRT; others never notice a meaningful change. DHT-related follicle miniaturization is gradual — acute shedding shortly after starting therapy is more likely telogen effluvium (a stress-response to hormonal change) than permanent loss.
Can you do TRT and keep your hair?
Many men do. Strategies discussed with clinicians include choosing ester and delivery-route combinations that produce lower DHT spikes, adding a topical 5-alpha reductase inhibitor like finasteride or dutasteride (both FDA-approved for hair loss), or using minoxidil concurrently. The right combination depends on your goals and genetics.
Does stopping TRT reverse hair loss?
Stopping TRT allows DHT levels to fall, which can slow or halt further androgenetic thinning. Hair that has already been lost due to follicle miniaturization typically does not regrow spontaneously. Hair loss caused by telogen effluvium (a temporary shed) may resolve after levels stabilize.
What is the DHT-to-testosterone ratio and why does it matter?
Not all testosterone converts to DHT at the same rate. The 5-alpha reductase enzyme varies in activity between individuals and between delivery routes. Injected testosterone enanthate or cypionate tends to produce moderate DHT conversion; topical gels and creams applied to the skin can produce disproportionately high DHT because skin is rich in 5-alpha reductase. This is one reason route of administration matters for hair-conscious patients.
Is finasteride safe to take with TRT?
Finasteride is an FDA-approved oral 5-alpha reductase inhibitor used for both benign prostatic hyperplasia and androgenetic alopecia. It can be co-prescribed with TRT by a licensed clinician. It lowers DHT substantially but does not prevent testosterone itself from acting. Side effects, including libido and mood changes, should be discussed with your prescribing clinician.